BioBusiness

Most Recent

Supersize my Pipeline

By | April 1, 2009

Will Exelixis's novel approach pay off in the current economic climate?

0 Comments

Personalized Meddling

By | March 1, 2009

Frankie Trull wants to sell your company to Congress.

3 Comments

Profiting from Pluripotency

By | February 1, 2009

How companies plan to make money (really) off of embryonic stem cells.

0 Comments

The Mentorship Market

By | January 1, 2009

New organizations want to help you succeed in biotech - for free.

3 Comments

Morale Mire

By | December 1, 2008

FDA scientists are increasingly unhappy, due to in-house pressures and public criticism. How can the agency restore what it once was?

2 Comments

Serotonin, Repurposed

By | November 1, 2008

Immune Control CEO Stephen Roth is banking on a controversial hypothesis and is fashioning ways to block a neurotransmitter to fight autoimmune disease.

0 Comments

The Orphan Drug Act Turns 25

By | October 1, 2008

The legislation is credited with building biotech and spawning hundreds of drugs for rare diseases. So why do some analysts hesitate to call it a success?

4 Comments

Chasing Challenges

By | September 1, 2008

AstraZeneca's Karen Gotting-Smith is using a newly-created position to tackle some old problems.

2 Comments

Success from Failure

By | August 1, 2008

John Prakash was once denied a job because of the way he looked. Now he spends his career talking about why diversity is crucial to drug development.

0 Comments

Irreverent Genetics

By | July 1, 2008

At Merck, Eric Schadt takes an iconoclastic approach to drug discovery - and dressing.

0 Comments

Popular Now

  1. Infant Microbiome: Vaginal Delivery Versus C-Section
  2. Immune System Maintains Brain Health
  3. Opinion: WHO’s Silence on Cannabis
  4. Top 10 Innovations 2016
    Features Top 10 Innovations 2016

    This year’s list of winners celebrates both large leaps and small (but important) steps in life science technology.

Rockland